Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18646745rdf:typepubmed:Citationlld:pubmed
pubmed-article:18646745lifeskim:mentionsumls-concept:C0020792lld:lifeskim
pubmed-article:18646745lifeskim:mentionsumls-concept:C0031727lld:lifeskim
pubmed-article:18646745lifeskim:mentionsumls-concept:C0243077lld:lifeskim
pubmed-article:18646745pubmed:issue15lld:pubmed
pubmed-article:18646745pubmed:dateCreated2008-8-7lld:pubmed
pubmed-article:18646745pubmed:abstractTextThe design, synthesis and biological evaluation of a series of 4-aminopyrazolylpyrimidines as potent Trk kinase inhibitors is reported. High-throughput screening identified a promising hit in the 4-aminopyrazolylpyrimidine chemotype. Initial optimization of the series led to more potent Trk inhibitors. Further optimization using two strategies resulted in significant improvement of physical properties and led to the discovery of 10z (AZ-23), a potent, orally bioavailable Trk A/B inhibitor. The compound offers the potential to test the hypothesis that modulation of Trk activity will be of benefit in the treatment of cancer and other indications in vivo.lld:pubmed
pubmed-article:18646745pubmed:languageenglld:pubmed
pubmed-article:18646745pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18646745pubmed:citationSubsetIMlld:pubmed
pubmed-article:18646745pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18646745pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18646745pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18646745pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18646745pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18646745pubmed:statusMEDLINElld:pubmed
pubmed-article:18646745pubmed:monthAuglld:pubmed
pubmed-article:18646745pubmed:issn1520-4804lld:pubmed
pubmed-article:18646745pubmed:authorpubmed-author:WoodR WRWlld:pubmed
pubmed-article:18646745pubmed:authorpubmed-author:ThouinLLlld:pubmed
pubmed-article:18646745pubmed:authorpubmed-author:HoffmannEthan...lld:pubmed
pubmed-article:18646745pubmed:authorpubmed-author:ScottDavid...lld:pubmed
pubmed-article:18646745pubmed:authorpubmed-author:WangTaoTlld:pubmed
pubmed-article:18646745pubmed:authorpubmed-author:JoseyJohn AJAlld:pubmed
pubmed-article:18646745pubmed:authorpubmed-author:HanYongxinYlld:pubmed
pubmed-article:18646745pubmed:authorpubmed-author:LambMichelle...lld:pubmed
pubmed-article:18646745pubmed:authorpubmed-author:WangHaixiaHlld:pubmed
pubmed-article:18646745pubmed:authorpubmed-author:MohrPeter JPJlld:pubmed
pubmed-article:18646745pubmed:authorpubmed-author:BlockMichael...lld:pubmed
pubmed-article:18646745pubmed:authorpubmed-author:LeeJohn WJWlld:pubmed
pubmed-article:18646745pubmed:authorpubmed-author:GuFeiFlld:pubmed
pubmed-article:18646745pubmed:authorpubmed-author:LynePaul DPDlld:pubmed
pubmed-article:18646745pubmed:authorpubmed-author:DaviesAudrey...lld:pubmed
pubmed-article:18646745pubmed:authorpubmed-author:HaiyunWangWlld:pubmed
pubmed-article:18646745pubmed:authorpubmed-author:ZhangHai-JunH...lld:pubmed
pubmed-article:18646745pubmed:authorpubmed-author:YuDingweiDlld:pubmed
pubmed-article:18646745pubmed:authorpubmed-author:ZhuYanyiYlld:pubmed
pubmed-article:18646745pubmed:authorpubmed-author:KausRobert...lld:pubmed
pubmed-article:18646745pubmed:authorpubmed-author:MacintyreTerr...lld:pubmed
pubmed-article:18646745pubmed:authorpubmed-author:OmerCharles...lld:pubmed
pubmed-article:18646745pubmed:issnTypeElectroniclld:pubmed
pubmed-article:18646745pubmed:day14lld:pubmed
pubmed-article:18646745pubmed:volume51lld:pubmed
pubmed-article:18646745pubmed:ownerNLMlld:pubmed
pubmed-article:18646745pubmed:authorsCompleteYlld:pubmed
pubmed-article:18646745pubmed:pagination4672-84lld:pubmed
pubmed-article:18646745pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:18646745pubmed:meshHeadingpubmed-meshheading:18646745...lld:pubmed
pubmed-article:18646745pubmed:meshHeadingpubmed-meshheading:18646745...lld:pubmed
pubmed-article:18646745pubmed:meshHeadingpubmed-meshheading:18646745...lld:pubmed
pubmed-article:18646745pubmed:meshHeadingpubmed-meshheading:18646745...lld:pubmed
pubmed-article:18646745pubmed:meshHeadingpubmed-meshheading:18646745...lld:pubmed
pubmed-article:18646745pubmed:meshHeadingpubmed-meshheading:18646745...lld:pubmed
pubmed-article:18646745pubmed:meshHeadingpubmed-meshheading:18646745...lld:pubmed
pubmed-article:18646745pubmed:meshHeadingpubmed-meshheading:18646745...lld:pubmed
pubmed-article:18646745pubmed:meshHeadingpubmed-meshheading:18646745...lld:pubmed
pubmed-article:18646745pubmed:meshHeadingpubmed-meshheading:18646745...lld:pubmed
pubmed-article:18646745pubmed:meshHeadingpubmed-meshheading:18646745...lld:pubmed
pubmed-article:18646745pubmed:meshHeadingpubmed-meshheading:18646745...lld:pubmed
pubmed-article:18646745pubmed:meshHeadingpubmed-meshheading:18646745...lld:pubmed
pubmed-article:18646745pubmed:meshHeadingpubmed-meshheading:18646745...lld:pubmed
pubmed-article:18646745pubmed:year2008lld:pubmed
pubmed-article:18646745pubmed:articleTitleIdentification of 4-aminopyrazolylpyrimidines as potent inhibitors of Trk kinases.lld:pubmed
pubmed-article:18646745pubmed:affiliationDepartment of Cancer Chemistry, AstraZeneca R&D Boston, Waltham, Massachusetts 02451, USA. tao.wang@astrazeneca.comlld:pubmed
pubmed-article:18646745pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:18646745lld:chembl